Airain ltd decreased its stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 33.8% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 64,699 shares of the medical instruments supplier’s stock after selling 33,051 shares during the period. Airain ltd’s holdings in DENTSPLY SIRONA were worth $4,195,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Dupont Capital Management Corp acquired a new position in DENTSPLY SIRONA during the second quarter valued at about $116,000. Korea Investment CORP boosted its position in DENTSPLY SIRONA by 139.9% in the second quarter. Korea Investment CORP now owns 2,145 shares of the medical instruments supplier’s stock valued at $139,000 after buying an additional 1,251 shares during the period. Penserra Capital Management LLC boosted its position in DENTSPLY SIRONA by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,760 shares of the medical instruments supplier’s stock valued at $172,000 after buying an additional 240 shares during the period. Meiji Yasuda Asset Management Co Ltd. acquired a new position in DENTSPLY SIRONA during the second quarter valued at about $203,000. Finally, Ballentine Partners LLC acquired a new position in DENTSPLY SIRONA during the second quarter valued at about $203,000. 93.97% of the stock is currently owned by hedge funds and other institutional investors.

Shares of DENTSPLY SIRONA Inc. (NASDAQ XRAY) opened at 54.80 on Monday. The firm has a 50-day moving average price of $59.93 and a 200 day moving average price of $62.08. DENTSPLY SIRONA Inc. has a 12-month low of $52.53 and a 12-month high of $65.68. The company’s market capitalization is $12.58 billion.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Wednesday, August 9th. The medical instruments supplier reported $0.65 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.65. The firm had revenue of $992.70 million during the quarter, compared to the consensus estimate of $1 billion. DENTSPLY SIRONA had a negative net margin of 20.57% and a positive return on equity of 7.24%. The firm’s revenue was down 2.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.76 earnings per share. On average, equities research analysts predict that DENTSPLY SIRONA Inc. will post $2.68 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 13th. Investors of record on Friday, September 29th will be given a $0.0875 dividend. The ex-dividend date is Thursday, September 28th. This represents a $0.35 dividend on an annualized basis and a yield of 0.64%. DENTSPLY SIRONA’s payout ratio is currently -10.09%.

WARNING: This news story was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://theolympiareport.com/2017/08/28/dentsply-sirona-inc-xray-shares-sold-by-airain-ltd.html.

Several research firms have recently issued reports on XRAY. HC Wainwright reissued a “buy” rating and set a $68.00 target price (down from $74.00) on shares of DENTSPLY SIRONA in a research note on Monday, August 14th. UBS AG restated a “neutral” rating and set a $59.00 price target (down from $62.00) on shares of DENTSPLY SIRONA in a research report on Thursday, August 10th. Stifel Nicolaus restated a “buy” rating and set a $66.00 price target (down from $70.00) on shares of DENTSPLY SIRONA in a research report on Thursday, August 10th. Jefferies Group LLC dropped their price target on DENTSPLY SIRONA from $72.00 to $66.00 and set a “buy” rating on the stock in a research report on Wednesday, August 23rd. Finally, Morgan Stanley lifted their price target on DENTSPLY SIRONA from $66.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, August 10th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $66.08.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY).

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.